Home Biosimilar Antibodies Immunology & Inflammation CD markers Tregalizumab (Anti-CD4)
For research use only. Not for use in humans.

Tregalizumab (Anti-CD4)

Synonyms: T4， L3T4

Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD.

Tregalizumab (Anti-CD4)

Quality Control

Batch: A282002 Purity: 99% Protein concentration: 10.85mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD.
References

Product Details

CAS No. 1207446-68-1
Molecular Weight 147.42
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05582694 WITHDRAWN Multi-Drug Resistant Hiv-1 Infection; HIV-1 Infection National Institute of Allergy and Infectious Diseases (NIAID) 2025-07-10 PHASE2
NCT04673591 COMPLETED Drug: Tregalizumab Allergy to House Dust Mite; Allergic Asthma T-Balance Therapeutics GmbH 2020-12-09 PHASE2
NCT00904254 UNKNOWN Carotid Stenosis Technische Universität Dresden 2015-01 PHASE2
NCT01999192 TERMINATED Drug: Tregalizumab|Drug: Placebo Rheumatoid Arthritis Biotest 2013-10 PHASE2
NCT01160445 TERMINATED Drug: Zanolimumab|Drug: Aldesleukin Metastatic Melanoma; Metastatic Renal Cancer National Cancer Institute (NCI) 2010-06 PHASE2
NCT00372177 COMPLETED Rheumatoid Arthritis; Polyarthritis; Rheumatism; Autoimmune Disease; Inflammation Biotectid GmbH 2007-07 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-07-11)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.